Home
At a glance
Contact us
Home
»
Media
»
Press Releases
Moapar® - Salvacyl®
Date
Article Title
21 Jul 2009
Swissmedic grants Debiopharm marketing authorisation for Moapar® - A new therapeutic avenue for the treatment of sexual deviations
23 Jun 2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations -
15 May 2008
Debiopharm Signs License Agreement for Marketing of Salvacyl®/Moapar 3-month for Sexual Deviations
23 May 2007
Salvacyl®/ Maopar® 3-month obtains european mutual recognition to treat sexual deviations
20 Jun 2006
Moapar® 3-months approved for the lowering of testosterone to castrate serum levels for control of sexual drive in adult men
Latest News
09 November 2011
Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease
05 October 2011
The Japanese Cancer Association and Debiopharm Group™ present Doctors Arakawa and Kurokawa with the 2011 ‘JCA-Mauvernay Award’for their innovative and outstanding research in the field of cancer
08 September 2011
Debiopharm Group™ presents the ‘Debiopharm Group™ Life Sciences Award 2011’ and two ‘Junior Debiopharm Group™ Awards 2011’ at the ISREC 2011 Life Sciences Symposium
About us
Our business
Responsibility
Careers
Media
Press Releases
Publications
Download center
Events
Debiopharm on
Legal Notice
Credits
Sitemap
© 2012 Debiopharm Group
